Fenspiride

Chemical compound

R03BX01 (WHO) R03DX03 (WHO)

Legal statusLegal status

In general: ℞ (Prescription only)

Pharmacokinetic dataBioavailability90%^[1]Elimination half-life14–16 hoursExcretionUrine (90%), feces (~10%)Identifiers

IUPAC name

8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one

CAS Number

5053-06-5^Y

PubChem CID

68626

DrugBank

DB08979^N

ChemSpider

3227^N

UNII

S983QC7HKM

KEGG

D07949^Y

ChEMBL

ChEMBL576127^N

CompTox Dashboard (EPA)

DTXSID4023048

ECHA InfoCard100.023.411

Chemical and physical dataFormulaC₁₅H₂₀N₂O₂Molar mass260.337 g·mol⁻¹3D model (JSmol)

Interactive image

SMILES

c1ccc(cc1)CCN2CCC3(CC2)CN=C(O3)O

InChI

InChI=1S/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)^N
Key:FVNFBBAOMBJTST-UHFFFAOYSA-N^N

^NY (what is this?) (verify)

Fenspiride (INN, brand names Eurespal, Pneumorel and others) is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases.^[2] The pharmacotherapeutic classification is antitussives. In Russia it was approved for the treatment of acute and chronic inflammatory diseases of ENT organs (ear, nose, throat) and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis), as well as for maintenance treatment of asthma.^[3] Russia, Romania, France and other European countries withdrew fenspiride-based drugs from the market due to the risk of QT prolongation and torsades de pointes.^[4] Fenspiride is known to have activity as an alpha-1 blocker, H1 antagonist, it also inhibits PDE3, PDE4, PDE5 with -logIC50 values of 3.44, 4.16, 3.8 respectively.^[5]

References

^ Montes B, Catalan M, Roces A, Jeanniot JP, Honorato JM (1993). "Single dose pharmacokinetics of fenspiride hydrochloride: phase I clinical trial". European Journal of Clinical Pharmacology. 45 (2): 169–72. doi:10.1007/bf00315501. PMID 7901024. S2CID 20605939.
^ Płusa T, Nawacka D (December 1998). "[Efficacy and tolerance of fenspiride in adult patients with acute respiratory tract infections]". Polski Merkuriusz Lekarski. 5 (30): 368–71. PMID 10101527.
^ "Эреспал (Eurespal) Prescribing Information. VIDAL Drug Compendium" (in Russian). Retrieved 6 February 2014.
^ "Fenspiride containing medicinal products". European Medicines Agency. 2019-02-15. Retrieved 2019-06-12.
^ Jankowski R (September 2002). "[ENT inflammation and importance of fenspiride]". Presse Med (in French). 31 Spec No 1: HS7–10. PMID 12378970.

Drugs for obstructive airway diseases: asthma/COPD (R03)

Adrenergics, inhalants

Short-acting β₂ agonists	Bitolterol Carbuterol Fenoterol Isoetarine Pirbuterol Procaterol Reproterol Rimiterol Salbutamol (albuterol)^#/Levosalbutamol (levalbuterol) Terbutaline Tulobuterol
Long-acting β₂ agonists	Bambuterol Clenbuterol Formoterol/Arformoterol Salmeterol Salmefamol
Ultra-long-acting β₂ agonists	Abediterol Carmoterol Indacaterol Olodaterol Vilanterol
Other	Epinephrine^# Hexoprenaline Isoprenaline (isoproterenol) Orciprenaline (metaproterenol)

Glucocorticoids

Anticholinergics/
muscarinic antagonist

Mast cell stabilizers

Xanthines

Eicosanoid inhibition

Leukotriene antagonists	Montelukast Pranlukast Zafirlukast
Arachidonate 5-lipoxygenase inhibitors	Zileuton
Thromboxane receptor antagonists	Ramatroban Seratrodast
Non-xanthine PDE4 inhibitors	Ibudilast Roflumilast